ANDROGENETIC ALOPECIA
Clinical trials for ANDROGENETIC ALOPECIA explained in plain language.
Never miss a new study
Get alerted when new ANDROGENETIC ALOPECIA trials appear
Sign up with your email to follow new studies for ANDROGENETIC ALOPECIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Baldness breakthrough? new pill VDPHL01 heads to final testing
Disease control OngoingThis study tests a new daily pill, VDPHL01, for male pattern baldness (androgenetic alopecia). About 480 men aged 18 to 65 with mild to moderate hair loss will take either the drug or a placebo for 13 months. The main goal is to see if the drug increases hair count and if partici…
Matched conditions: ANDROGENETIC ALOPECIA
Phase: PHASE3 • Sponsor: Veradermics, Inc. • Aim: Disease control
Last updated Jun 18, 2026 11:51 UTC
-
Withdrawn hair loss study sought to regrow hair with stem cells and platelets
Disease control TerminatedThis study aimed to see if a mixture of platelet-rich plasma and stem cells from fat tissue could safely and effectively treat hair loss in men and women. It planned to compare different combinations of these substances injected into the scalp. However, the study was withdrawn be…
Matched conditions: ANDROGENETIC ALOPECIA
Phase: PHASE1, PHASE2 • Sponsor: Healeon Medical Inc • Aim: Disease control
Last updated Jun 17, 2026 12:09 UTC
-
New hair loss pill shows promise in early trial
Disease control OngoingThis study tests an experimental oral drug called VDPHL01 for people with mild to moderate pattern baldness (androgenetic alopecia). About 70 men and women aged 18-65 will take the pill daily for 12 months to see if it safely increases hair count and improves appearance. The drug…
Matched conditions: ANDROGENETIC ALOPECIA
Phase: PHASE2 • Sponsor: Veradermics, Inc. • Aim: Disease control
Last updated Jun 17, 2026 12:07 UTC
-
New pill could help men regrow hair
Disease control OngoingThis study tests an experimental oral drug called VDPHL01 for male pattern baldness (androgenetic alopecia). About 480 men aged 18 to 65 with mild to moderate hair loss will take either the drug or a placebo for 6 months, then all will receive the active drug for another 6 months…
Matched conditions: ANDROGENETIC ALOPECIA
Phase: PHASE2, PHASE3 • Sponsor: Veradermics, Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC